Who spends the most on TV drug ads?
Prescription medications ranked by TVPills internal editorial estimates of annual TV ad budgets. These are not measured year-to-date or realized full-year spending.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
Estimated Annual Budget Total
$13.2B
Drugs Ranked
145
- 1
Humira
USadalimumab · Rheumatoid arthritis, psoriasis, Crohn's disease
Unverified catalogue summary (leaderboard identity and indication) for Humira in US; not checked against current local product information.
$500M
editorial est. / yr · catalogue record
- 2
Skyrizi
USrisankizumab-rzaa · Plaque psoriasis, psoriatic arthritis, Crohn's disease
Unverified catalogue summary (leaderboard identity and indication) for Skyrizi in US; not checked against current local product information.
$480M
editorial est. / yr · catalogue record
- 3
Ozempic
USsemaglutide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Ozempic in US; not checked against current local product information.
$420M
editorial est. / yr · catalogue record
- 4
Dupixent
USdupilumab · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Dupixent in US; not checked against current local product information.
$390M
editorial est. / yr · catalogue record
- 5
Wegovy
USsemaglutide · Chronic weight management, cardiovascular risk reduction
Unverified catalogue summary (leaderboard identity and indication) for Wegovy in US; not checked against current local product information.
$380M
editorial est. / yr · catalogue record
- 6
Eliquis
USapixaban · Blood clots, nonvalvular atrial fibrillation
Unverified catalogue summary (leaderboard identity and indication) for Eliquis in US; not checked against current local product information.
$350M
editorial est. / yr · catalogue record
- 7
Mounjaro
UStirzepatide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Mounjaro in US; not checked against current local product information.
$350M
editorial est. / yr · catalogue record
- 8
Zepbound
UStirzepatide · Chronic weight management, obstructive sleep apnea
Unverified catalogue summary (leaderboard identity and indication) for Zepbound in US; not checked against current local product information.
$300M
editorial est. / yr · catalogue record
- 9
Jardiance
USempagliflozin · Type 2 diabetes, heart failure, chronic kidney disease
Unverified catalogue summary (leaderboard identity and indication) for Jardiance in US; not checked against current local product information.
$280M
editorial est. / yr · catalogue record
- 10
Keytruda
USpembrolizumab · Multiple cancers
Unverified catalogue summary (leaderboard identity and indication) for Keytruda in US; not checked against current local product information.
$260M
editorial est. / yr · catalogue record
- 11
Trulicity
USdulaglutide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Trulicity in US; not checked against current local product information.
$240M
editorial est. / yr · catalogue record
- 12
Farxiga
USdapagliflozin · Type 2 diabetes, heart failure, chronic kidney disease
Unverified catalogue summary (leaderboard identity and indication) for Farxiga in US; not checked against current local product information.
$220M
editorial est. / yr · catalogue record
- 13
Xarelto
USrivaroxaban · Blood clots, nonvalvular atrial fibrillation
Unverified catalogue summary (leaderboard identity and indication) for Xarelto in US; not checked against current local product information.
$210M
editorial est. / yr · catalogue record
- 14
Vraylar
UScariprazine · Schizophrenia (age 13+), bipolar I mania/mixed episodes (age 10+), adult bipolar I depression, adult MDD (add-on)
Unverified catalogue summary (leaderboard identity and indication) for Vraylar in US; not checked against current local product information.
$200M
editorial est. / yr · catalogue record
- 15
Trelegy Ellipta
USfluticasone furoate/umeclidinium/vilanterol · COPD, asthma
Unverified catalogue summary (leaderboard identity and indication) for Trelegy Ellipta in US; not checked against current local product information.
$200M
editorial est. / yr · catalogue record
- 16
Taltz
USixekizumab · Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis
Unverified catalogue summary (leaderboard identity and indication) for Taltz in US; not checked against current local product information.
$190M
editorial est. / yr · catalogue record
- 17
Nurtec ODT
USrimegepant · Adult migraine: acute treatment and episodic prevention
Unverified catalogue summary (leaderboard identity and indication) for Nurtec ODT in US; not checked against current local product information.
$190M
editorial est. / yr · catalogue record
- 18
Rybelsus
USsemaglutide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Rybelsus in US; not checked against current local product information.
$180M
editorial est. / yr · catalogue record
- 19
Biktarvy
USbictegravir/emtricitabine/tenofovir alafenamide · HIV-1 infection
Unverified catalogue summary (leaderboard identity and indication) for Biktarvy in US; not checked against current local product information.
$180M
editorial est. / yr · catalogue record
- 20
Rinvoq
USupadacitinib · Rheumatoid arthritis, psoriatic arthritis, eczema
Unverified catalogue summary (leaderboard identity and indication) for Rinvoq in US; not checked against current local product information.
$175M
editorial est. / yr · catalogue record
- 21
Rexulti
USbrexpiprazole · Adult major depression (add-on), schizophrenia (age 13+), agitation associated with dementia due to Alzheimer's disease
Unverified catalogue summary (leaderboard identity and indication) for Rexulti in US; not checked against current local product information.
$170M
editorial est. / yr · catalogue record
- 22
Cosentyx
USsecukinumab · Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis
Unverified catalogue summary (leaderboard identity and indication) for Cosentyx in US; not checked against current local product information.
$160M
editorial est. / yr · catalogue record
- 23
Ubrelvy
USubrogepant · Acute migraine
Unverified catalogue summary (leaderboard identity and indication) for Ubrelvy in US; not checked against current local product information.
$160M
editorial est. / yr · catalogue record
- 24
Entresto
USsacubitril/valsartan · Chronic heart failure
Unverified catalogue summary (leaderboard identity and indication) for Entresto in US; not checked against current local product information.
$150M
editorial est. / yr · catalogue record
- 25
Opdivo
USnivolumab · Multiple cancers
Unverified catalogue summary (leaderboard identity and indication) for Opdivo in US; not checked against current local product information.
$150M
editorial est. / yr · catalogue record
- 26
Austedo
USdeutetrabenazine · Tardive dyskinesia, Huntington's chorea
Unverified catalogue summary (leaderboard identity and indication) for Austedo in US; not checked against current local product information.
$150M
editorial est. / yr · catalogue record
- 27
Xiidra
USlifitegrast · Dry eye disease
Unverified catalogue summary (leaderboard identity and indication) for Xiidra in US; not checked against current local product information.
$150M
editorial est. / yr · catalogue record
- 28
Shingrix
USzoster vaccine recombinant, adjuvanted · Shingles prevention
Unverified catalogue summary (leaderboard identity and indication) for Shingrix in US; not checked against current local product information.
$150M
editorial est. / yr · catalogue record
- 29
Tremfya
USguselkumab · Plaque psoriasis, psoriatic arthritis
Unverified catalogue summary (leaderboard identity and indication) for Tremfya in US; not checked against current local product information.
$140M
editorial est. / yr · catalogue record
- 30
Linzess
USlinaclotide · IBS with constipation (age 7+), adult chronic idiopathic constipation, pediatric functional constipation (age 2+)
Unverified catalogue summary (leaderboard identity and indication) for Linzess in US; not checked against current local product information.
$140M
editorial est. / yr · catalogue record
- 31
Myrbetriq
USmirabegron · Overactive bladder
Unverified catalogue summary (leaderboard identity and indication) for Myrbetriq in US; not checked against current local product information.
$140M
editorial est. / yr · catalogue record
- 32
Stelara
USustekinumab · Psoriasis, Crohn's disease, ulcerative colitis
Unverified catalogue summary (leaderboard identity and indication) for Stelara in US; not checked against current local product information.
$130M
editorial est. / yr · catalogue record
- 33
Caplyta
USlumateperone · Adult schizophrenia, bipolar I/II depression, major depression (add-on)
Unverified catalogue summary (leaderboard identity and indication) for Caplyta in US; not checked against current local product information.
$130M
editorial est. / yr · catalogue record
- 34
Trintellix
USvortioxetine · Major depressive disorder
Unverified catalogue summary (leaderboard identity and indication) for Trintellix in US; not checked against current local product information.
$130M
editorial est. / yr · catalogue record
- 35
Xifaxan
USrifaximin · Irritable bowel syndrome with diarrhea, hepatic encephalopathy
Unverified catalogue summary (leaderboard identity and indication) for Xifaxan in US; not checked against current local product information.
$130M
editorial est. / yr · catalogue record
- 36
Sotyktu
USdeucravacitinib · Adult moderate-to-severe plaque psoriasis; adult active psoriatic arthritis
Unverified catalogue summary (leaderboard identity and indication) for Sotyktu in US; not checked against current local product information.
$130M
editorial est. / yr · catalogue record
- 37
Repatha
USevolocumab · High cholesterol, cardiovascular disease
Unverified catalogue summary (leaderboard identity and indication) for Repatha in US; not checked against current local product information.
$120M
editorial est. / yr · catalogue record
- 38
Qulipta
USatogepant · Migraine prevention
Unverified catalogue summary (leaderboard identity and indication) for Qulipta in US; not checked against current local product information.
$120M
editorial est. / yr · catalogue record
- 39
Breztri Aerosphere
USbudesonide/glycopyrrolate/formoterol · Maintenance COPD in adults; maintenance asthma (age 12+)
Unverified catalogue summary (leaderboard identity and indication) for Breztri Aerosphere in US; not checked against current local product information.
$120M
editorial est. / yr · catalogue record
- 40
Brilinta
USticagrelor · Acute coronary syndrome, heart attack prevention
Unverified catalogue summary (leaderboard identity and indication) for Brilinta in US; not checked against current local product information.
$120M
editorial est. / yr · catalogue record
- 41
Prolia
USdenosumab · Osteoporosis
Unverified catalogue summary (leaderboard identity and indication) for Prolia in US; not checked against current local product information.
$120M
editorial est. / yr · catalogue record
- 42
Symbicort
USbudesonide/formoterol · Asthma, COPD
Unverified catalogue summary (leaderboard identity and indication) for Symbicort in US; not checked against current local product information.
$120M
editorial est. / yr · catalogue record
- 43
Otezla
USapremilast · Plaque psoriasis, psoriatic arthritis, oral ulcers associated with Behçet's disease
Unverified catalogue summary (leaderboard identity and indication) for Otezla in US; not checked against current local product information.
$110M
editorial est. / yr · catalogue record
- 44
Veozah
USfezolinetant · Menopausal hot flashes
Unverified catalogue summary (leaderboard identity and indication) for Veozah in US; not checked against current local product information.
$110M
editorial est. / yr · catalogue record
- 45
Invokana
UScanagliflozin · Type 2 diabetes, diabetic kidney disease
Unverified catalogue summary (leaderboard identity and indication) for Invokana in US; not checked against current local product information.
$110M
editorial est. / yr · catalogue record
- 46
Emgality
USgalcanezumab-gnlm · Migraine prevention and episodic cluster headache in adults
Unverified catalogue summary (leaderboard identity and indication) for Emgality in US; not checked against current local product information.
$110M
editorial est. / yr · catalogue record
- 47
Arexvy
USrespiratory syncytial virus vaccine, recombinant, adjuvanted · Prevention of RSV lower respiratory tract disease in adults 60+ and adults 18–59 at increased risk
Unverified catalogue summary (leaderboard identity and indication) for Arexvy in US; not checked against current local product information.
$110M
editorial est. / yr · catalogue record
- 48
Restasis
UScyclosporine ophthalmic emulsion · Reduced tear production associated with ocular inflammation in keratoconjunctivitis sicca
Unverified catalogue summary (leaderboard identity and indication) for Restasis in US; not checked against current local product information.
$100M
editorial est. / yr · catalogue record
- 49
Aimovig
USerenumab-aooe · Migraine prevention
Unverified catalogue summary (leaderboard identity and indication) for Aimovig in US; not checked against current local product information.
$100M
editorial est. / yr · catalogue record
- 50
Breo Ellipta
USfluticasone furoate/vilanterol · Asthma, COPD
Unverified catalogue summary (leaderboard identity and indication) for Breo Ellipta in US; not checked against current local product information.
$100M
editorial est. / yr · catalogue record
- 51
Cialis
UStadalafil · Erectile dysfunction, enlarged prostate (BPH)
Unverified catalogue summary (leaderboard identity and indication) for Cialis in US; not checked against current local product information.
$100M
editorial est. / yr · catalogue record
- 52
Humira
CAadalimumab · Rheumatoid arthritis, psoriasis, Crohn's disease
Unverified catalogue summary (leaderboard identity and indication) for Humira in CA; not checked against current local product information.
$95M
editorial est. / yr · catalogue record
- 53
Entyvio
USvedolizumab · Ulcerative colitis, Crohn's disease
Unverified catalogue summary (leaderboard identity and indication) for Entyvio in US; not checked against current local product information.
$95M
editorial est. / yr · catalogue record
- 54
Xolair
USomalizumab · Allergic asthma, chronic spontaneous urticaria and IgE-mediated food allergy
Unverified catalogue summary (leaderboard identity and indication) for Xolair in US; not checked against current local product information.
$95M
editorial est. / yr · catalogue record
- 55
Dovato
USdolutegravir/lamivudine · HIV-1 infection
Unverified catalogue summary (leaderboard identity and indication) for Dovato in US; not checked against current local product information.
$95M
editorial est. / yr · catalogue record
- 56
Leqvio
USinclisiran · High cholesterol
Unverified catalogue summary (leaderboard identity and indication) for Leqvio in US; not checked against current local product information.
$90M
editorial est. / yr · catalogue record
- 57
Vascepa
USicosapent ethyl · High triglycerides, cardiovascular risk reduction
Unverified catalogue summary (leaderboard identity and indication) for Vascepa in US; not checked against current local product information.
$90M
editorial est. / yr · catalogue record
- 58
Eylea
USaflibercept · Wet macular degeneration, diabetic eye disease
Unverified catalogue summary (leaderboard identity and indication) for Eylea in US; not checked against current local product information.
$90M
editorial est. / yr · catalogue record
- 59
Xeljanz
UStofacitinib · Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis
Unverified catalogue summary (leaderboard identity and indication) for Xeljanz in US; not checked against current local product information.
$90M
editorial est. / yr · catalogue record
- 60
Chantix
USvarenicline · Smoking cessation
Unverified catalogue summary (leaderboard identity and indication) for Chantix in US; not checked against current local product information.
$90M
editorial est. / yr · catalogue record
- 61
Xtandi
USenzalutamide · Prostate cancer
Unverified catalogue summary (leaderboard identity and indication) for Xtandi in US; not checked against current local product information.
$90M
editorial est. / yr · catalogue record
- 62
Ozempic
CAsemaglutide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Ozempic in CA; not checked against current local product information.
$85M
editorial est. / yr · catalogue record
- 63
Verzenio
USabemaciclib · HR+/HER2- breast cancer
Unverified catalogue summary (leaderboard identity and indication) for Verzenio in US; not checked against current local product information.
$85M
editorial est. / yr · catalogue record
- 64
Vabysmo
USfaricimab-svoa · Wet macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion
Unverified catalogue summary (leaderboard identity and indication) for Vabysmo in US; not checked against current local product information.
$85M
editorial est. / yr · catalogue record
- 65
Latuda
USlurasidone · Schizophrenia and depressive episodes associated with bipolar I disorder
Unverified catalogue summary (leaderboard identity and indication) for Latuda in US; not checked against current local product information.
$85M
editorial est. / yr · catalogue record
- 66
Ibrance
USpalbociclib · HR-positive advanced or metastatic breast cancer, in specified HER2-negative and HER2-positive combination regimens
Unverified catalogue summary (leaderboard identity and indication) for Ibrance in US; not checked against current local product information.
$80M
editorial est. / yr · catalogue record
- 67
Gemtesa
USvibegron · Overactive bladder
Unverified catalogue summary (leaderboard identity and indication) for Gemtesa in US; not checked against current local product information.
$80M
editorial est. / yr · catalogue record
- 68
Fasenra
USbenralizumab · Severe eosinophilic asthma
Unverified catalogue summary (leaderboard identity and indication) for Fasenra in US; not checked against current local product information.
$80M
editorial est. / yr · catalogue record
- 69
Mavyret
USglecaprevir/pibrentasvir · Hepatitis C
Unverified catalogue summary (leaderboard identity and indication) for Mavyret in US; not checked against current local product information.
$80M
editorial est. / yr · catalogue record
- 70
Kisqali
USribociclib · HR-positive, HER2-negative breast cancer
Unverified catalogue summary (leaderboard identity and indication) for Kisqali in US; not checked against current local product information.
$80M
editorial est. / yr · catalogue record
- 71
Eliquis
CAapixaban · Blood clots, atrial fibrillation
Unverified catalogue summary (leaderboard identity and indication) for Eliquis in CA; not checked against current local product information.
$75M
editorial est. / yr · catalogue record
- 72
Cibinqo
USabrocitinib · Refractory moderate-to-severe atopic dermatitis in patients 12 years and older
Unverified catalogue summary (leaderboard identity and indication) for Cibinqo in US; not checked against current local product information.
$75M
editorial est. / yr · catalogue record
- 73
Nucala
USmepolizumab · Severe eosinophilic asthma, COPD, nasal polyps
Unverified catalogue summary (leaderboard identity and indication) for Nucala in US; not checked against current local product information.
$75M
editorial est. / yr · catalogue record
- 74
Quviviq
USdaridorexant · Insomnia
Unverified catalogue summary (leaderboard identity and indication) for Quviviq in US; not checked against current local product information.
$75M
editorial est. / yr · catalogue record
- 75
Vuity
USpilocarpine ophthalmic · Age-related blurry near vision (presbyopia)
Unverified catalogue summary (leaderboard identity and indication) for Vuity in US; not checked against current local product information.
$70M
editorial est. / yr · catalogue record
- 76
Evenity
USromosozumab-aqqg · Osteoporosis in postmenopausal women at high fracture risk
Unverified catalogue summary (leaderboard identity and indication) for Evenity in US; not checked against current local product information.
$70M
editorial est. / yr · catalogue record
- 77
Ajovy
USfremanezumab-vfrm · Migraine prevention
Unverified catalogue summary (leaderboard identity and indication) for Ajovy in US; not checked against current local product information.
$70M
editorial est. / yr · catalogue record
- 78
Tezspire
UStezepelumab-ekko · Severe asthma
Unverified catalogue summary (leaderboard identity and indication) for Tezspire in US; not checked against current local product information.
$70M
editorial est. / yr · catalogue record
- 79
Vyvanse
USlisdexamfetamine · ADHD, binge eating disorder
Unverified catalogue summary (leaderboard identity and indication) for Vyvanse in US; not checked against current local product information.
$70M
editorial est. / yr · catalogue record
- 80
Dupixent
CAdupilumab · Moderate-to-severe atopic dermatitis, severe type 2/eosinophilic or oral corticosteroid-dependent asthma, severe chronic rhinosinusitis with nasal polyps
Unverified catalogue summary (leaderboard identity and indication) for Dupixent in CA; not checked against current local product information.
$65M
editorial est. / yr · catalogue record
- 81
Litfulo
USritlecitinib · Severe alopecia areata
Unverified catalogue summary (leaderboard identity and indication) for Litfulo in US; not checked against current local product information.
$65M
editorial est. / yr · catalogue record
- 82
Icotyde
USicotrokinra · Plaque psoriasis
Unverified catalogue summary (leaderboard identity and indication) for Icotyde in US; not checked against current local product information.
$65M
editorial est. / yr · catalogue record
- 83
Lipitor
USatorvastatin · High cholesterol, cardiovascular prevention
Unverified catalogue summary (leaderboard identity and indication) for Lipitor in US; not checked against current local product information.
$60M
editorial est. / yr · catalogue record
- 84
Kerendia
USfinerenone · CKD associated with type 2 or type 1 diabetes; heart failure with LVEF ≥40%
Unverified catalogue summary (leaderboard identity and indication) for Kerendia in US; not checked against current local product information.
$60M
editorial est. / yr · catalogue record
- 85
Olumiant
USbaricitinib · Rheumatoid arthritis, severe alopecia areata
Unverified catalogue summary (leaderboard identity and indication) for Olumiant in US; not checked against current local product information.
$60M
editorial est. / yr · catalogue record
- 86
Paxlovid
USnirmatrelvir/ritonavir · Mild-to-moderate COVID-19 in adults at high risk for progression to severe disease
Unverified catalogue summary (leaderboard identity and indication) for Paxlovid in US; not checked against current local product information.
$60M
editorial est. / yr · catalogue record
- 87
Orilissa
USelagolix · Endometriosis pain
Unverified catalogue summary (leaderboard identity and indication) for Orilissa in US; not checked against current local product information.
$60M
editorial est. / yr · catalogue record
- 88
Jardiance
CAempagliflozin · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Jardiance in CA; not checked against current local product information.
$55M
editorial est. / yr · catalogue record
- 89
Bimzelx
USbimekizumab-bkzx · Plaque psoriasis, psoriatic arthritis
Unverified catalogue summary (leaderboard identity and indication) for Bimzelx in US; not checked against current local product information.
$55M
editorial est. / yr · catalogue record
- 90
Auvelity
USdextromethorphan/bupropion · Major depressive disorder in adults; agitation associated with dementia due to Alzheimer's disease
Unverified catalogue summary (leaderboard identity and indication) for Auvelity in US; not checked against current local product information.
$50M
editorial est. / yr · catalogue record
- 91
Skyrizi
CArisankizumab · Plaque psoriasis, psoriatic arthritis, Crohn's disease
Unverified catalogue summary (leaderboard identity and indication) for Skyrizi in CA; not checked against current local product information.
$48M
editorial est. / yr · catalogue record
- 92
Crestor
USrosuvastatin · High cholesterol, cardiovascular prevention
Unverified catalogue summary (leaderboard identity and indication) for Crestor in US; not checked against current local product information.
$45M
editorial est. / yr · catalogue record
- 93
Keytruda
CApembrolizumab · Multiple cancers
Unverified catalogue summary (leaderboard identity and indication) for Keytruda in CA; not checked against current local product information.
$42M
editorial est. / yr · catalogue record
- 94
Mounjaro
CAtirzepatide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Mounjaro in CA; not checked against current local product information.
$40M
editorial est. / yr · catalogue record
- 95
Rinvoq
CAupadacitinib · Rheumatoid arthritis, psoriatic arthritis, eczema
Unverified catalogue summary (leaderboard identity and indication) for Rinvoq in CA; not checked against current local product information.
$38M
editorial est. / yr · catalogue record
- 96
Repatha
CAevolocumab · High cholesterol, cardiovascular disease
Unverified catalogue summary (leaderboard identity and indication) for Repatha in CA; not checked against current local product information.
$32M
editorial est. / yr · catalogue record
- 97
Victoza
CAliraglutide · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Victoza in CA; not checked against current local product information.
$28M
editorial est. / yr · catalogue record
- 98
Xarelto
CArivaroxaban · Blood clots, atrial fibrillation
Unverified catalogue summary (leaderboard identity and indication) for Xarelto in CA; not checked against current local product information.
$28M
editorial est. / yr · catalogue record
- 99
Trulicity
CAdulaglutide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Trulicity in CA; not checked against current local product information.
$26M
editorial est. / yr · catalogue record
- 100
Tylenol
CAacetaminophen · Pain relief, fever
Unverified catalogue summary (leaderboard identity and indication) for Tylenol in CA; not checked against current local product information.
$14M
editorial est. / yr · catalogue record
- 101
Advair
CAfluticasone propionate/salmeterol · Maintenance treatment of asthma; COPD maintenance with Advair Diskus 250 or 500
Unverified catalogue summary (leaderboard identity and indication) for Advair in CA; not checked against current local product information.
$12M
editorial est. / yr · catalogue record
- 102
Voltaren
NZdiclofenac · Arthritis, muscle pain, joint pain
Unverified catalogue summary (leaderboard identity and indication) for Voltaren in NZ; not checked against current local product information.
$12M
editorial est. / yr · catalogue record
- 103
Symbicort
CAbudesonide/formoterol · Asthma, COPD
Unverified catalogue summary (leaderboard identity and indication) for Symbicort in CA; not checked against current local product information.
$11M
editorial est. / yr · catalogue record
- 104
Nurofen
NZibuprofen · Pain relief, inflammation, fever
Unverified catalogue summary (leaderboard identity and indication) for Nurofen in NZ; not checked against current local product information.
$10M
editorial est. / yr · catalogue record
- 105
Nexium
CAesomeprazole · Acid reflux, GERD, ulcers
Unverified catalogue summary (leaderboard identity and indication) for Nexium in CA; not checked against current local product information.
$9M
editorial est. / yr · catalogue record
- 106
Lipitor
CAatorvastatin · High cholesterol, cardiovascular prevention
Unverified catalogue summary (leaderboard identity and indication) for Lipitor in CA; not checked against current local product information.
$8M
editorial est. / yr · catalogue record
- 107
Nasonex
NZmometasone · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Nasonex in NZ; not checked against current local product information.
$8M
editorial est. / yr · catalogue record
- 108
Nicorette
NZnicotine · Smoking cessation
Unverified catalogue summary (leaderboard identity and indication) for Nicorette in NZ; not checked against current local product information.
$8M
editorial est. / yr · catalogue record
- 109
Crestor
CArosuvastatin · High cholesterol, cardiovascular prevention
Unverified catalogue summary (leaderboard identity and indication) for Crestor in CA; not checked against current local product information.
$7M
editorial est. / yr · catalogue record
- 110
Ventolin
CAsalbutamol · Asthma, bronchospasm
Unverified catalogue summary (leaderboard identity and indication) for Ventolin in CA; not checked against current local product information.
$6M
editorial est. / yr · catalogue record
- 111
Nexium
NZesomeprazole · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Nexium in NZ; not checked against current local product information.
$6M
editorial est. / yr · catalogue record
- 112
Claratyne
NZloratadine · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Claratyne in NZ; not checked against current local product information.
$6M
editorial est. / yr · catalogue record
- 113
Synthroid
CAlevothyroxine sodium · Hypothyroidism
Unverified catalogue summary (leaderboard identity and indication) for Synthroid in CA; not checked against current local product information.
$5M
editorial est. / yr · catalogue record
- 114
Panadol
NZparacetamol · Pain relief, fever
Unverified catalogue summary (leaderboard identity and indication) for Panadol in NZ; not checked against current local product information.
$5M
editorial est. / yr · catalogue record
- 115
Fosamax
NZalendronate · Osteoporosis
Unverified catalogue summary (leaderboard identity and indication) for Fosamax in NZ; not checked against current local product information.
$5M
editorial est. / yr · catalogue record
- 116
Cipralex
CAescitalopram · Depression, anxiety
Unverified catalogue summary (leaderboard identity and indication) for Cipralex in CA; not checked against current local product information.
$4M
editorial est. / yr · catalogue record
- 117
Telfast
NZfexofenadine · Hay fever, allergic rhinitis, hives
Unverified catalogue summary (leaderboard identity and indication) for Telfast in NZ; not checked against current local product information.
$4M
editorial est. / yr · catalogue record
- 118
Champix
NZvarenicline · Smoking cessation
Unverified catalogue summary (leaderboard identity and indication) for Champix in NZ; not checked against current local product information.
$4M
editorial est. / yr · catalogue record
- 119
Zyrtec
NZcetirizine · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Zyrtec in NZ; not checked against current local product information.
$4M
editorial est. / yr · catalogue record
- 120
Lipitor
NZatorvastatin · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Lipitor in NZ; not checked against current local product information.
$4M
editorial est. / yr · catalogue record
- 121
Concerta
CAmethylphenidate hydrochloride · ADHD
Unverified catalogue summary (leaderboard identity and indication) for Concerta in CA; not checked against current local product information.
$3M
editorial est. / yr · catalogue record
- 122
Losec
NZomeprazole · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Losec in NZ; not checked against current local product information.
$3M
editorial est. / yr · catalogue record
- 123
Ozempic
NZsemaglutide · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Ozempic in NZ; not checked against current local product information.
$3M
editorial est. / yr · catalogue record
- 124
Otrivin
NZxylometazoline · Nasal congestion, cold and sinus relief
Unverified catalogue summary (leaderboard identity and indication) for Otrivin in NZ; not checked against current local product information.
$3M
editorial est. / yr · catalogue record
- 125
Ventolin
NZsalbutamol · Asthma, bronchospasm
Unverified catalogue summary (leaderboard identity and indication) for Ventolin in NZ; not checked against current local product information.
$3M
editorial est. / yr · catalogue record
- 126
Symbicort
NZbudesonide/formoterol · Asthma, COPD
Unverified catalogue summary (leaderboard identity and indication) for Symbicort in NZ; not checked against current local product information.
$3M
editorial est. / yr · catalogue record
- 127
Altace
CAramipril · High blood pressure, heart protection
Unverified catalogue summary (leaderboard identity and indication) for Altace in CA; not checked against current local product information.
$2M
editorial est. / yr · catalogue record
- 128
Glucophage
CAmetformin hydrochloride · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Glucophage in CA; not checked against current local product information.
$2M
editorial est. / yr · catalogue record
- 129
Pantoloc
CApantoprazole · Acid reflux, GERD, ulcers
Unverified catalogue summary (leaderboard identity and indication) for Pantoloc in CA; not checked against current local product information.
$2M
editorial est. / yr · catalogue record
- 130
Seretide
NZfluticasone propionate/salmeterol · Asthma, COPD
Unverified catalogue summary (leaderboard identity and indication) for Seretide in NZ; not checked against current local product information.
$2M
editorial est. / yr · catalogue record
- 131
Jardiance
NZempagliflozin · Type 2 diabetes, heart failure
Unverified catalogue summary (leaderboard identity and indication) for Jardiance in NZ; not checked against current local product information.
$2M
editorial est. / yr · catalogue record
- 132
Metformin
USmetformin · Type 2 diabetes
Unverified catalogue summary (leaderboard identity and indication) for Metformin in US; not checked against current local product information.
$2M
editorial est. / yr · catalogue record
- 133
Cymbalta
NZduloxetine · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Cymbalta in NZ; not checked against current local product information.
$2M
editorial est. / yr · catalogue record
- 134
Glucophage
NZmetformin · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Glucophage in NZ; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 135
Augmentin
NZamoxicillin/clavulanate · Bacterial infections
Unverified catalogue summary (leaderboard identity and indication) for Augmentin in NZ; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 136
Loxalate
NZescitalopram · Depression, anxiety
Unverified catalogue summary (leaderboard identity and indication) for Loxalate in NZ; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 137
Mobic
NZmeloxicam · Arthritis, joint inflammation
Unverified catalogue summary (leaderboard identity and indication) for Mobic in NZ; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 138
Somac
NZpantoprazole · See official local label
Unverified catalogue summary (leaderboard identity and indication) for Somac in NZ; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 139
Lisinopril
USlisinopril · High blood pressure, heart failure
Unverified catalogue summary (leaderboard identity and indication) for Lisinopril in US; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 140
Amoxicillin
USamoxicillin · Bacterial infections
Unverified catalogue summary (leaderboard identity and indication) for Amoxicillin in US; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 141
Gabapentin
USgabapentin · Adult postherpetic neuralgia; partial-onset seizures (add-on, age 3+)
Unverified catalogue summary (leaderboard identity and indication) for Gabapentin in US; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 142
Adderall
USamphetamine/dextroamphetamine · ADHD, narcolepsy
Unverified catalogue summary (leaderboard identity and indication) for Adderall in US; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 143
Synthroid
USlevothyroxine · Hypothyroidism
Unverified catalogue summary (leaderboard identity and indication) for Synthroid in US; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 144
Prednisone
USprednisone · Inflammation, autoimmune flares, allergic reactions
Unverified catalogue summary (leaderboard identity and indication) for Prednisone in US; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
- 145
Zoloft
USsertraline · Major depression, OCD, panic disorder, PTSD, social anxiety disorder, PMDD
Unverified catalogue summary (leaderboard identity and indication) for Zoloft in US; not checked against current local product information.
$1M
editorial est. / yr · catalogue record
TV drug ad spend: frequently asked questions
Which prescription drug spends the most on TV advertising?
Humira has the largest estimated TV ad budget at about $500M a year in TVPills' internal editorial estimates, ranking first among the drugs we track. This is not verified spending.
How much do prescription drugs spend on TV ads in total?
The 145 TV-advertised drugs in the selected country filter have a combined TVPills internal editorial estimate of annual TV ad budgets of about $13.2B. This is not measured spending.
Why do drug companies advertise so much on TV?
Prescription drugs are among the most heavily advertised products on American television because direct-to-consumer ads encourage patients to ask their doctors about brand-name medicines — which can drive significant sales for high-priced drugs.
Which countries allow prescription drug ads on TV?
Only the United States and New Zealand allow full direct-to-consumer prescription drug advertising, so nearly all TV drug ad spending happens in those two countries.
Sources & methodology
Source dataset: TVPills maintained drug catalogue (TVPills Editorial Team). The catalogue snapshot used for these figures was retrieved June 30, 2026.
Calculation: Each drug record's tvAdBudgetMillions value is treated as an estimated annual budget in millions of US dollars. Rankings sort records descending by that value; totals and group totals sum each positive record once, without weighting or extrapolating from commercial counts. Each individual amount in the rankings links to the corresponding catalogue record; grouped totals use the same record-level values.
Limitations: These values are editorial estimates, not company-reported or independently audited media-buying figures. The catalogue does not currently attach a public third-party publication to each estimate, so the figures should not be used as financial, investment, or market-size data.
Source status: Internal editorial estimate. No company filing or independent media-buying dataset is being presented as the source for these values.
Embed this leaderboard
Run a health, news, or finance site? Drop this leaderboard into any page — it stays up to date automatically. Please keep the credit link.